Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients

R. Duchnowska, PJ. Wysocki, K. Korski, B. Czartoryska-Arłukowicz, A. Niwińska, M. Orlikowska, B. Radecka, M. Studziński, R. Demlova, B. Ziółkowska, M. Merdalska, Ł. Hajac, P. Myśliwiec, D. Zuziak, S. Dębska-Szmich, I. Lang, M. Foszczyńska-Kłoda,...

. 2016 ; 7 (1) : 550-64.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17000829

UNLABELLED: Molecular mechanisms of lapatinib resistance in breast cancer are not well understood. The aim of this study was to correlate expression of selected proteins involved in ErbB family signaling pathways with clinical efficacy of lapatinib. Study group included 270 HER2-positive advanced breast cancer patients treated with lapatinib and capecitabine. Immunohistochemical expression of phosphorylated adenosine monophosphate-activated protein (p-AMPK), mitogen-activated protein kinase (p-MAPK), phospho (p)-p70S6K, cyclin E, phosphatase and tensin homolog were analyzed in primary breast cancer samples. The best discriminative value for progression-free survival (PFS) was established for each biomarker and subjected to multivariate analysis. At least one biomarker was determined in 199 patients. Expression of p-p70S6K was independently associated with longer (HR 0.45; 95% CI: 0.25-0.81; p = 0.009), and cyclin E with shorter PFS (HR 1.83; 95% CI: 1.06-3.14; p = 0.029). Expression of p-MAPK (HR 1.61; 95% CI 1.13-2.29; p = 0.009) and cyclin E (HR 2.99; 95% CI: 1.29-6.94; p = 0.011) was correlated with shorter, and expression of estrogen receptor (HR 0.65; 95% CI 0.43-0.98; p = 0.041) with longer overall survival. Expression of p-AMPK negatively impacted response to treatment (HR 3.31; 95% CI 1.48-7.44; p = 0.004) and disease control (HR 3.07; 95% CI 1.25-7.58; p = 0.015). IN CONCLUSION: the efficacy of lapatinib seems to be associated with the activity of downstream signaling pathways - AMPK/mTOR and Ras/Raf/MAPK. Further research is warranted to assess the clinical utility of these data and to determine a potential role of combining lapatinib with MAPK pathway inhibitors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000829
003      
CZ-PrNML
005      
20170517080550.0
007      
ta
008      
170103s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.6375 $2 doi
024    7_
$a 10.18632/oncotarget.6375 $2 doi
035    __
$a (PubMed)26623720
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Duchnowska, Renata $u Military Institute of Medicine, Oncology Department, Warsaw, Poland.
245    10
$a Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients / $c R. Duchnowska, PJ. Wysocki, K. Korski, B. Czartoryska-Arłukowicz, A. Niwińska, M. Orlikowska, B. Radecka, M. Studziński, R. Demlova, B. Ziółkowska, M. Merdalska, Ł. Hajac, P. Myśliwiec, D. Zuziak, S. Dębska-Szmich, I. Lang, M. Foszczyńska-Kłoda, B. Karczmarek-Borowska, A. Żawrocki, A. Kowalczyk, W. Biernat, J. Jassem, . ,
520    9_
$a UNLABELLED: Molecular mechanisms of lapatinib resistance in breast cancer are not well understood. The aim of this study was to correlate expression of selected proteins involved in ErbB family signaling pathways with clinical efficacy of lapatinib. Study group included 270 HER2-positive advanced breast cancer patients treated with lapatinib and capecitabine. Immunohistochemical expression of phosphorylated adenosine monophosphate-activated protein (p-AMPK), mitogen-activated protein kinase (p-MAPK), phospho (p)-p70S6K, cyclin E, phosphatase and tensin homolog were analyzed in primary breast cancer samples. The best discriminative value for progression-free survival (PFS) was established for each biomarker and subjected to multivariate analysis. At least one biomarker was determined in 199 patients. Expression of p-p70S6K was independently associated with longer (HR 0.45; 95% CI: 0.25-0.81; p = 0.009), and cyclin E with shorter PFS (HR 1.83; 95% CI: 1.06-3.14; p = 0.029). Expression of p-MAPK (HR 1.61; 95% CI 1.13-2.29; p = 0.009) and cyclin E (HR 2.99; 95% CI: 1.29-6.94; p = 0.011) was correlated with shorter, and expression of estrogen receptor (HR 0.65; 95% CI 0.43-0.98; p = 0.041) with longer overall survival. Expression of p-AMPK negatively impacted response to treatment (HR 3.31; 95% CI 1.48-7.44; p = 0.004) and disease control (HR 3.07; 95% CI 1.25-7.58; p = 0.015). IN CONCLUSION: the efficacy of lapatinib seems to be associated with the activity of downstream signaling pathways - AMPK/mTOR and Ras/Raf/MAPK. Further research is warranted to assess the clinical utility of these data and to determine a potential role of combining lapatinib with MAPK pathway inhibitors.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádory prsu $x farmakoterapie $x metabolismus $x patologie $7 D001943
650    _2
$a cyklin E $x metabolismus $7 D019927
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $x metody $7 D007150
650    _2
$a Kaplanův-Meierův odhad $7 D053208
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mitogenem aktivované proteinkinasy $x metabolismus $7 D020928
650    _2
$a hodnocení výsledků zdravotní péče $x metody $x statistika a číselné údaje $7 D017063
650    _2
$a fosforylace $x účinky léků $7 D010766
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prognóza $7 D011379
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    _2
$a chinazoliny $x terapeutické užití $7 D011799
650    _2
$a receptor erbB-2 $x antagonisté a inhibitory $x metabolismus $7 D018719
650    _2
$a receptory pro estrogeny $x metabolismus $7 D011960
650    _2
$a kinasy ribozomálního proteinu S6, 70-kDa $x metabolismus $7 D038762
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Wysocki, Piotr J $u West Pomeranian Cancer Center, Szczecin, Poland.
700    1_
$a Korski, Konstanty $u Greater Poland Cancer Center, Poznań, Poland.
700    1_
$a Czartoryska-Arłukowicz, Bogumiła $u Białystok Oncology Center, Białystok, Poland.
700    1_
$a Niwińska, Anna $u The Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
700    1_
$a Orlikowska, Marlena $u Warmia and Masuria Oncology Center, Olsztyn, Poland.
700    1_
$a Radecka, Barbara $u Opole Oncology Center, Poland.
700    1_
$a Studziński, Maciej $u Oncology Center, Bydgoszcz, Poland.
700    1_
$a Demlova, Regina $u Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Ziółkowska, Barbara $u Chemotherapy Department, Regional Hospital, Wrocław, Poland.
700    1_
$a Merdalska, Monika $u Oncology Center, Kielce, Poland.
700    1_
$a Hajac, Łukasz $u Oncology Center, Wrocław, Poland.
700    1_
$a Myśliwiec, Paulina $u Oncology Center, Zielona Góra, Poland.
700    1_
$a Zuziak, Dorota $u Oncology Center, Bielsko-Biała, Poland.
700    1_
$a Dębska-Szmich, Sylwia $u Medical University of Łódź, Łódź, Poland.
700    1_
$a Lang, Istvan $u Department of Medical Oncology, National Institute of Oncology, Budapest, Hungary.
700    1_
$a Foszczyńska-Kłoda, Małgorzata $u West Pomeranian Cancer Center, Szczecin, Poland.
700    1_
$a Karczmarek-Borowska, Bożenna $u Department of Chemotherapy, Subcarpathian Oncology Center, Rzeszów, Poland.
700    1_
$a Żawrocki, Anton $u Medical University of Gdańsk, Gdańsk, Poland.
700    1_
$a Kowalczyk, Anna $u Medical University of Gdańsk, Gdańsk, Poland.
700    1_
$a Biernat, Wojciech $u Medical University of Gdańsk, Gdańsk, Poland. $7 xx0213526
700    1_
$a Jassem, Jacek $u Medical University of Gdańsk, Gdańsk, Poland.
700    1_
$a ,
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 1 (2016), s. 550-64
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26623720 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170517080937 $b ABA008
999    __
$a ok $b bmc $g 1179969 $s 961396
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 1 $d 550-64 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20170103

Najít záznam

Citační ukazatele

Možnosti archivace